<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
<url><loc>https://majorhealthnews.com/press-releases/eloxx-pharmaceuticals-announces-publication-of-phase-2a-exaluren-data-in-nonsense</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T21:07:55.436Z</news:publication_date><news:title>Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/racura-oncology-receives-first-site-approval-for-seamless-phase-2b3-emili-trial-of-rc220</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T12:54:10.183Z</news:publication_date><news:title>Racura Oncology Receives First Site Approval for Seamless Phase 2b/3 EMILI Trial of RC220 in Relapsed or Refractory Acute Myeloid Leukemia</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/biolinerx-enters-into-dollar56-million-royalty-monetization-transaction-with-soleus</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T12:19:16.294Z</news:publication_date><news:title>BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/harbour-biomeds-partner-spruce-biosciences-separates-crhx-101-program-into-adrenyx</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-18T00:20:16.358Z</news:publication_date><news:title>Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/inhibrx-announces-updated-clinical-data-for-ozekibart-inbrx-109-in-ewing-sarcoma</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T22:03:37.036Z</news:publication_date><news:title>Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/labcorp-to-expand-clinical-trial-operations-in-brazil-with-dedicated-kit-assembly-and</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T21:55:51.339Z</news:publication_date><news:title>Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/westernu-college-of-pharmacy-awarded-hrsa-grant-to-train-pharmacists-to-practice-in</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T21:05:58.224Z</news:publication_date><news:title>WesternU College of Pharmacy awarded HRSA grant to train pharmacists to practice in medically vulnerable communities</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/recovery-centers-of-america-at-mount-dora-expands-insurance-access-with-aetna-and-cigna</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T19:56:35.372Z</news:publication_date><news:title>Recovery Centers of America at Mount Dora Expands Insurance Access with Aetna and Cigna</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/clean-eatz-builds-on-q3-sales-growth-with-new-menu-and-plans-for-2027-restaurant-prototype</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T17:03:50.562Z</news:publication_date><news:title>Clean Eatz Builds on Q3 Sales Growth with New Menu and Plans for 2027 Restaurant Prototype</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/ichnos-glenmark-innovation-igi-announces-ind-submission-to-us-fda-for-isb-2301-a-first-in</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T16:57:53.303Z</news:publication_date><news:title>Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors</news:title></news:news></url>
<url><loc>https://majorhealthnews.com/press-releases/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing</loc><news:news><news:publication><news:name>Major Health News</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T12:17:11.564Z</news:publication_date><news:title>SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia</news:title></news:news></url>
</urlset>